{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.lifitegrast","code":"thing-q23044263","url":"https://ver.cy/models/thing/q23044263/","name":"lifitegrast","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Lifitegrast is a small-molecule antagonist of lymphocyte function-associated antigen-1 (LFA-1) that inhibits its interaction with intercellular adhesion molecule-1 (ICAM-1) and is used in ophthalmic treatment of dry eye disease.","purpose":"Enable an agent to identify lifitegrast, assess the identity and quality of a material lot, and determine its suitability for a specified research or pharmaceutical use.","scope":{"in":["Molecular structure, stereochemistry and verified substance identifiers","Free-acid identity and relationships to salts, solvates and formulated ingredients","Lot-specific assay, impurities, grade and traceability","Physical form, solubility and stability under recorded conditions","LFA-1 interaction evidence and substance-level handling constraints"],"out":["Finished ophthalmic products, their containers, excipients and administration instructions","Patient-specific diagnosis, prescribing and treatment decisions","Dry eye disease as a clinical condition","Manufacturing processes, facilities and their operational qualification","LFA-1 and ICAM-1 as independently modeled biological entities"],"boundaries":[]},"distinguishingFeatures":["Match the complete molecular structure and specified S stereochemistry; a matching name or molecular formula alone cannot exclude another stereoisomer.","Use C29H24Cl2N2O7S and molecular weight 615.5 g/mol as identity cross-checks for the parent substance, rather than applying them unchanged to salts or solvates.","Distinguish the active substance from a lifitegrast ophthalmic solution: solution concentration, excipients and sterility describe the product.","Require structure-based identification to distinguish lifitegrast from other dry-eye agents; shared therapeutic use or anti-inflammatory activity does not establish identity.","Treat LFA-1 interaction as supporting functional evidence, not as a uniquely identifying chemical test."],"structure":{"bundles":[{"id":"lifitegrast-chemical-identity","name":"Lifitegrast chemical identity","description":"Establishes the parent structure, stereochemistry and boundary between lifitegrast and related material forms.","layers":[{"id":"parent-structure","name":"Parent structure","description":"Defines the molecular identity against which candidate materials are checked.","findings":[{"id":"structure-and-stereochemistry","name":"Structure and stereochemistry","description":"The prescribing information identifies an S-configured parent substance with formula C29H24Cl2N2O7S and molecular weight 615.5 g/mol. [DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1d4b4b61-79da-4b6f-bb19-056d111bf400).","questions":[{"text":"Which stereochemistry-explicit structure and analytical identity tests define lifitegrast for this record?","id":"structure-and-stereochemistry-q01","kind":"definition"},{"text":"Which authoritative records verify the CAS number, PubChem CID, UNII and any applicable EC identifier against that exact structure?","id":"structure-and-stereochemistry-q02","kind":"provenance"}]}]},{"id":"related-forms-and-products","name":"Related forms and products","description":"Separates chemical-form variants and formulated products from the parent identity.","findings":[{"id":"parent-equivalent-boundary","name":"Parent-equivalent boundary","description":"A salt, hydrated material or ophthalmic solution requires an explicit relationship to the parent substance and a stated quantity basis.","questions":[{"text":"Does the material designation mean parent lifitegrast, an identified salt or solvate, or a mixture containing lifitegrast?","id":"parent-equivalent-boundary-q01","kind":"boundary"},{"text":"What form-specific conversion is needed to express the reported quantity as parent lifitegrast?","id":"parent-equivalent-boundary-q02","kind":"measurement"}]}]}]},{"id":"lifitegrast-lot-quality","name":"Lifitegrast lot quality","description":"Connects measured composition and traceability to the suitability of a specific lifitegrast lot.","layers":[{"id":"assay-and-related-substances","name":"Assay and related substances","description":"Records parent content separately from stereochemical and other impurity measurements.","findings":[{"id":"quantified-lot-composition","name":"Quantified lot composition","description":"The proposed model requires assay basis, chiral purity and relevant impurity results rather than one ambiguous purity percentage.","questions":[{"text":"What are the lifitegrast mass assay and stereochemical purity, and which methods and reference standards support them?","id":"quantified-lot-composition-q01","kind":"measurement"},{"text":"Which process-related impurities, degradation products, residual solvents and other contaminants must be controlled for the intended use?","id":"quantified-lot-composition-q02","kind":"boundary"}]}]},{"id":"grade-and-disposition","name":"Grade and disposition","description":"Associates lot history and specifications with explicit release decisions.","findings":[{"id":"use-specific-release","name":"Use-specific release","description":"Research-grade and pharmaceutical-use claims need traceable evidence; neither establishes that bulk lifitegrast is ready for ocular administration.","questions":[{"text":"Which manufacturer, lot identifier, certificate and approved specification establish the claimed grade?","id":"use-specific-release-q01","kind":"provenance"},{"text":"Do the available results justify release for the stated use, or require quarantine, rejection or retesting?","id":"use-specific-release-q02","kind":"action"}]}]}]},{"id":"lifitegrast-physical-behavior","name":"Lifitegrast physical behavior","description":"Records condition-dependent solid-state, dissolution and degradation behavior.","layers":[{"id":"solid-state-and-dissolution","name":"Solid state and dissolution","description":"Relates material form to thermal measurements and solution preparation.","findings":[{"id":"form-conditioned-properties","name":"Form-conditioned properties","description":"Property values require identified material form and measurement conditions; unverified constants remain unresolved.","questions":[{"text":"What evidence identifies the solid form and distinguishes melting, desolvation and thermal decomposition events?","id":"form-conditioned-properties-q01","kind":"measurement"},{"text":"How do pH, solvent, temperature and parent-versus-salt form affect measured solubility and precipitation?","id":"form-conditioned-properties-q02","kind":"measurement"}]}]},{"id":"stability-and-retest","name":"Stability and retest","description":"Connects environmental exposure and elapsed time to chemical quality.","findings":[{"id":"supported-storage-window","name":"Supported storage window","description":"Storage and retest conditions must be supported for the actual bulk material or prepared solution.","questions":[{"text":"Which stability-indicating results establish sensitivity to light, moisture, temperature and solution conditions?","id":"supported-storage-window-q01","kind":"measurement"},{"text":"After a storage excursion or solution hold, what evidence is required before this material can be used?","id":"supported-storage-window-q02","kind":"action"}]}]}]},{"id":"lifitegrast-biological-function","name":"Lifitegrast biological function","description":"Links lifitegrast identity to target interaction and distinguishes assay evidence from clinical product claims.","layers":[{"id":"target-interaction","name":"Target interaction","description":"Records the biological relationship and conditions used to measure it.","findings":[{"id":"lfa1-icam1-interference","name":"LFA-1-ICAM-1 interference","description":"Lifitegrast binds LFA-1 and blocks its interaction with ICAM-1; the label states that its exact mechanism in dry eye disease is unknown. [DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1d4b4b61-79da-4b6f-bb19-056d111bf400).","questions":[{"text":"Which binding, adhesion or cellular assay supports the stated lifitegrast activity?","id":"lfa1-icam1-interference-q01","kind":"provenance"},{"text":"What potency was measured, with which endpoint, biological system, concentration basis and uncertainty?","id":"lfa1-icam1-interference-q02","kind":"measurement"}]}]},{"id":"activity-to-product-evidence","name":"Activity to product evidence","description":"Controls the transfer of evidence between substance assays and ophthalmic products.","findings":[{"id":"context-limited-extrapolation","name":"Context-limited extrapolation","description":"A target assay does not establish patient benefit, and product clinical findings do not qualify an arbitrary lifitegrast lot.","questions":[{"text":"Which claims concern isolated lifitegrast activity, and which depend on a specified ophthalmic formulation and clinical study?","id":"context-limited-extrapolation-q01","kind":"boundary"},{"text":"What additional comparability evidence is needed before substituting this material in a biological assay or formulation study?","id":"context-limited-extrapolation-q02","kind":"action"}]}]}]},{"id":"lifitegrast-handling-and-regulatory-context","name":"Lifitegrast handling and regulatory context","description":"Establishes evidence-based bulk handling constraints and jurisdiction-specific links to permitted uses.","layers":[{"id":"bulk-exposure-and-disposal","name":"Bulk exposure and disposal","description":"Records hazards for the actual lifitegrast material and operation.","findings":[{"id":"material-specific-hazard-evidence","name":"Material-specific hazard evidence","description":"The model requires a matched safety data sheet and explicit uncertainty where occupational or environmental evidence is missing.","questions":[{"text":"Which current safety data sheet supports the GHS classification and any occupational exposure limit or internal exposure band for this material?","id":"material-specific-hazard-evidence-q01","kind":"provenance"},{"text":"What containment, protective equipment and waste route are supported for weighing, dissolving or disposing of this lifitegrast lot?","id":"material-specific-hazard-evidence-q02","kind":"action"}]}]},{"id":"jurisdiction-and-use-status","name":"Jurisdiction and use status","description":"Connects substance identity to dated regulatory evidence without assigning product approval to bulk material.","findings":[{"id":"authorization-boundary","name":"Authorization boundary","description":"Regulatory records must identify the jurisdiction, date, regulated entity and specific use to which they apply.","questions":[{"text":"Which official records establish lifitegrast substance identity and the status of relevant medicinal products in the intended jurisdiction?","id":"authorization-boundary-q01","kind":"provenance"},{"text":"Which requirements attach to this bulk API and proposed use, and which belong to a finished-product authorization?","id":"authorization-boundary-q02","kind":"boundary"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of lifitegrast this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Explain lifitegrast as an LFA-1 antagonist eye drop for dry eye disease, citing official labelling.","Report approved use, warnings and side effects from the label."],"mustNot":["Recommend, dose or adjust lifitegrast for a specific person.","Suggest sharing eye drop containers between people.","Present it as a cure for all causes of dry eye.","Advise using it with contact lenses against the label instructions."],"requiresHuman":["Starting or changing a patient's eye treatment."]},"ethics":{"considerations":["Eye conditions affect quality of life and independence.","Medicine costs affect who can get treatment."],"affectedParties":["Patients with dry eye","Eye care professionals","Pharmacists"]},"owners":{"steward":"The prescriber and the pharmacist for each patient; medicines regulators authorize products.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.lifitegrast","Wikidata: Q23044263 (https://www.wikidata.org/wiki/Q23044263)"]},"properties":{"applicability":"required","items":["Molecular identity: Stereochemistry-explicit structure, formula C29H24Cl2N2O7S and verified identifier mappings","Molecular weight: 615.5 g/mol for the parent substance","Material form: Parent acid, identified salt, solvate or hydrate relationship; crystalline, amorphous or dissolved state","Lifitegrast assay: % w/w with as-is, dried or anhydrous basis and analytical method","Stereochemical purity: Specified stereoisomer percentage or enantiomeric excess, with chiral method","Impurity burden: % or ppm by named impurity, including residual solvents, water and elemental impurities where applicable","Conditional solubility: mg/mL or mol/L with solvent, pH, temperature, material form and equilibration method","LFA-1 antagonism: Lifitegrast-LFA-1 binding and LFA-1-ICAM-1 inhibition evidence, linked to assay conditions","Lot disposition: Unassessed, quarantined, released for specified use, rejected or retest due"]},"recognition":{"applicability":"required","items":["Identified by product label, active ingredient name and pack details rather than by appearance alone."]},"capabilities":{"applicability":"required","items":["Resolve a supplier label or substance identifier to lifitegrast and flag material-form mismatches.","Compare a lot certificate and analytical results with the specification for a stated use.","Calculate parent-substance equivalents using assay, water content and chemical-form corrections.","Assess whether proposed dissolution and storage conditions are supported by measured evidence.","Compare LFA-1 activity results only after reconciling assay conditions and concentration bases.","Link qualified substance lots to downstream products while preserving the distinction between API quality and finished-product release."]},"hazards":{"applicability":"required","items":["Eye irritation and blurred vision after use.","Taste disturbance.","Contamination of shared or reused containers."]},"interfaces":{"applicability":"required","items":["The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns lifitegrast code S01XA25 within other ophthalmologicals."]},"context":{"applicability":"required","items":["Lifitegrast is encountered in ophthalmic drug research and pharmaceutical development involving inflammation associated with dry eye disease.","It is used to study inhibition of the interaction between LFA-1 and ICAM-1 and the resulting effects on immune cell activity.","Material lots are evaluated in analytical, formulation and quality-control settings for their intended research or pharmaceutical use."]}},"sources":[{"title":"Wikidata item Q23044263: lifitegrast","url":"https://www.wikidata.org/wiki/Q23044263","note":"identity and sense of the item"},{"title":"Wikipedia: Lifitegrast","url":"https://en.wikipedia.org/wiki/Lifitegrast","note":"general description of the item"}],"openQuestions":["Which CAS, PubChem, UNII and EC records consistently identify the parent stereochemical structure, and which instead identify related forms?","Which solid forms, melting or decomposition measurements, pKa values and pH-dependent solubility data are supported by primary measurements?","What validated impurity specifications and stereochemical limits apply to lifitegrast intended for pharmaceutical manufacture?","What bulk-material stability data support storage conditions, retest periods and prepared-solution hold times?","Which jurisdiction-specific GHS classifications, occupational exposure controls and environmental disposal requirements are substantiated for bulk lifitegrast?"],"resources":{"spec":"/models/things/publications/thing-q23044263/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q23044263/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:58:10Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:28+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}